NervGen Pharma Corp. (NGEN) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · United States · ISIN CA64082X2032
NervGen Pharma Corp. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 0.00 CAD | 0.00 CAD |
| Gross profit | -83,741.00 CAD | – |
| Operating income | -24.92 m CAD | -25.08 m CAD |
| EBIT | -23.99 m CAD | -5.71 m CAD |
| Net income | -23.99 m CAD | -44.12 m CAD |
| Diluted EPS – continuing operations | -0.36 CAD | -0.61 CAD |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About NervGen Pharma Corp.
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
More stocks
- TS Corporation (001790.KS)
- Smart Eye AB (SEYE.ST)
- Wayi International Digital Entertainment Co (3086.TWO)
- Daehan Steel (084010.KS)
- QEP Co Inc (QEPC)
- Allgeier (AEIN.DE)
- MAKUS Inc (093520.KQ)
- FreightCar America, Inc. (RAIL)
- Optimum Communications, Inc. (OPTU)
- Yuan Jen Enterprises Co Ltd (1725.TW)
- Canada Nickel Company Inc (CNC.V)
- Msg Life ag (MSGL.HM)
Not investment advice. All data without warranty, price as of 05.11.2026. Details in the risk notice.